Pekin Hardy Strauss’s Maravai LifeSciences MRVI Stock Holding History

Pekin Hardy Strauss’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-12,000	Closed	-$28.9K	–	423
2025 Q2	$28.9K	Sell	12,000 -13,000	-52%	-$27.3K	﹤0.01%	359
2025 Q1	$55.3K	Buy	+25,000	New	+$98.8K	0.01%	358

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

MFS

Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Pekin Hardy Strauss's MRVI Position: Q3 2025 in Review

Pekin Hardy Strauss sold out of Maravai LifeSciences (MRVI) in Q3 2025, closing a stake of 12,000 shares — an estimated $28.9K sold.

Pekin Hardy Strauss first reported a position in MRVI in Q1 2025 and held it in 2 quarters. The position peaked at $55.3K in Q1 2025. 160 funds tracked by Wall St. Rank hold MRVI as of Q3 2025.

Pekin Hardy Strauss reported no remaining Maravai LifeSciences position as of Q3 2025 after selling out during the quarter.
Pekin Hardy Strauss sold 12,000 Maravai LifeSciences shares in Q3 2025, an estimated $28.9K.
Pekin Hardy Strauss first reported a position in Maravai LifeSciences in Q1 2025 and held it in 2 quarters.
Pekin Hardy Strauss's Maravai LifeSciences position peaked at $55.3K in Q1 2025.
160 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q3 2025.

Based on Pekin Hardy Strauss's 13F filing for Q3 2025, filed 10 Nov 2025.